The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
The first wave of shipments includes several countries, such as Germany, France and Austria
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The transaction as well as the open offer is expected to be completed by June this year.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
